Korean J Obstet Gynecol.  2011 Mar;54(3):127-131. 10.5468/KJOG.2011.54.3.127.

Prophylactic antiemetics therapy against gynecologic cancer chemotherapy

• Lee KH
• Kwon YI

• KMID: 2274026
• DOI: http://doi.org/10.5468/KJOG.2011.54.3.127

Abstract

Nausea and vomiting associated with gynecologic cancer chemotherapy are experienced by most of patients receiving chemotherapy. Assessment of vomiting risk by chemotherapy and risk factor are mandatory for rescue of chemotherapy induced nausea and vomiting (CINV). Piled-up evidence based medicine result in prophylactic antiemetics guideline from American Society of Clinical Oncology, Multinational Association for Supportive Care in Cancer, and National Comprehensive Cancer Network. Combination of serotonin receptor antagonist, dexamethason, and with/without NK1 antagonist is the best prophylaxis in patients receiving highly and moderate emetogenic chemotherapy. Other new regimens (palonosetron, transdermal granisetron) are introduced to relieve the active symptom of delayed CINV. Comprehensive understading of pathophysiology of CINV and tailored therapy for the patients are vital in prophylactic antiemetics therapy against gynecologic cancer chemotherapy.

Keyword

Nausea; Vomiting; Antiemetics; Guideline

MeSH Terms

Antiemetics
Evidence-Based Medicine
Humans
Medical Oncology
Nausea
Risk Factors
Serotonin
Vomiting
Antiemetics
Serotonin

Reference

1. Beger AM, Clark-Snow RA. Devita VT, Hellman S, Rosenberg SA, editors. Adverse effects of treatment. Cancer: principles & practice of oncology. 2001. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins;2869–2880.

2. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer. 2003. 39:1074–1080.

3. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008. 358:2482–2494.

4. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006. 24:2932–2947.

5. Antiemetic guidelines [Internet]. Multinational Association of Supportive Care in Cancer (MASCC). c2011. cited Sep 11, 2010. Hillerød (DK): MASCC;Available from: http://www.mascc.org/mc/page.do?sitePageId=88041.

6. Clinical practice guidelines in oncology. Antiemesis. Version 2 [Internet]. National Comprehensive Cancer Network (NCCN). c2011. cited Sep 11, 2010. Washington (PA): NCCN;Available from: http://www.nccn.org.

7. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol. 2006. 4:403–408.

8. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer. 2009. 17:589–594.

9. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008. 112:2080–2087.

10. Herrstedt J, Roila F. ESMO Guidelines Working Group. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2008. 19:Suppl 2. ii110–ii112.

11. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT₃ receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003. 98:2473–2482.

12. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003. 14:1570–1577.

13. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006. 17:1441–1449.

14. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009. 10:115–124.

15. Naeim A, Dy SM, Lorenz KA, Sanati H, Walling A, Asch SM. Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol. 2008. 26:3903–3910.